Serum steroids in relation to benign prostatic hyperplasia

Oncology (Switzerland)

Volumn 54, Issue 6, 1997, Pages 497-501

  Lagiou, Pagona ^a,c   Mantzoros, Christos S ^a,b   Tzonou, Anastasia ^d   Signorello, Lisa B ^a   Lipworth, Loren ^a   Trichopoulos, Dimitrios ^a  

^a HARVARD CENTER FOR CANCER PREVENTION   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Boston University Medical Campus   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Benign prostatic hyperplasia; Dehydroepiandrosterone sulfate; Dihydrotestosterone; Estradiol; Sex hormone binding globulin; Testosterone

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; STEROID; TESTOSTERONE;

AGE; ARTICLE; BODY HEIGHT; BODY MASS; CONTROLLED STUDY; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REGRESSION ANALYSIS; SCHOOL; STATISTICS; STEROID BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; DIHYDROTESTOSTERONE; ESTRADIOL; GONADAL STEROID HORMONES; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; PROSTATIC HYPERPLASIA; RISK; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 0030809122     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227609     Document Type: Article

References (35)

1. Ekman P, Andersen JT, Wolf H: Finasteride in the treatment of benign prostatic hyperplasia, Acta Urol Belg 1996;64:IX-XII.
2. Stoner E: 5 Alpha-reductase inhibitors/finasteride, Prostate 1996;6:82-87.
3. Gormley GJ: Finasteride: A clinical review, Biomed Pharmacother 1995;49:319-324.
4. Schroder FH: 5 Alpha-reductase inhibitors and prostatic disease, Clin Endocrinol 1994;41: 139-147.
5. Gellcr J, Sionit L: Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride, J Cell Biochcm 1992; 16H: 109-112.
6. Vermeulcn A, De Sy W: Androgens in patients with benign prostatic hyperplasia before and after prostatectomy, J Clin Endocrinol Metab 1976;43:1250-1254.
7. Hammond GL, Kontturi M, Vihko P, Vihko R: Scrum steroids in normal males and patients with prostatic diseases, Clin Endocrinol 1978; 9:113-121.
8. Brochu M, Belanger A: Comparative study of plasma steroid and steroid glucuronidc levels in normal men and in men with benign prostatic hyperplasia, Prostate 1987; 11:33-40.
9. Gann PH, Hcnnekens CH, Longcopc C, Ver-hoek-Oftedahl W, Grodstein F, Stampfer MJ: A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia, Prostate 1995.26: 40-49.
10. Morimoto I, Eto S, Inoue S, Izumi M, Hara T, Saito Y, Nagataki S: Dihydrotestosterone accumulation in genital skin fibroblasts derived from elderly men with prostatic hyperplasia, J Clin Endocrinol Metab 1992;75:632-635.
11. Ghanadian R, Puah CM: Relationships between oestradiol-17 beta, testosterone, dihy-drotcstosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate, J Endocrinol 1981;88:255-262.
12. Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P, Steroid hormones and the pathogenesis of benign prostatic hyperplasia, Eur Urol 1991;20(suppl l):68-77.
13. Berry SJ, Coffey DS, Strandberg JD, Ewing LL: Effect of age, castration, and testosterone replacement on the development and restoration of canine benign prostatic hyperplasia, Prostate 1986;9:295-302.
14. Jaffe A, Matzkin H, Gilad S, Stem N: Effect of 5-alpha-reductase inhibition of sex-hormone-binding globulin in elderly men, Hormone Res 1994;41:215-217.
15. Signorello LB, Tzonou A, Mantzoros CS, Lip-worth L, Lagiou P, Hsich C-C, Stampfer M, Trichopoulos D: Serum steroids in relation to prostate cancer risk in a case-control study (Greece), Cancer Causes Control, in press.
16. Breslow NE, Day NE: Statistical Methods in Cancer Research, vol 1: The Analysis of Case-Control Studies, Lyon, International Agency for Research on Cancer, 1980, IARC Scientific Publication No 32.
17. MacMahon B, Trichopoulos D: Epidemiology Principles and Methods, Boston, Little, Brown, 1996.
18. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC: Longitudinal evaluation of serum androgen levels in men with and without prostate cancer, Prostate 1995;27:25-31.
19. Bartsch W, Becker H, Pinkenburg FA, Krieg M: Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH), Acta Endocrinol 1979;90:727-736.
20. Stcgc R, Carlstrom K: Testicular and adrenocortical function in healthy men and in men with benign prostatic hyperplasia, J Steroid Biochcm Mol Biol 1992;42:357-362.
21. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia, J Urol 1991;145:405-409.
22. Hulka BS, Hammond JE, DiFerdinando G, Mickey DD, Fried FA, Checkoway H, Stumpf WE, Beckman WC Jr., Clark TD: Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls, Prostate 1987:11:171-182.
23. Lukkarinen O: Total and SHBG-bound testosterone and 5 alpha-dihydrotestosterone serum concentrations in normal elderly men and patients with benign prostatic hypertrophy before and after removal of the adenoma, Br J Urol 1980;52:377-380.
24. Rannikko S, Adlcrcreutz H: Plasma estradiol, free testosterone, sex hormone-binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer, Prostate 1983:4:223-229.
25. Ortega E, Ruiz E, Mendoza MC, Martin-Ancres A, Osorio C: Plasma steroid and protein hormone concentration in patients with ben:gn prostatic hypertrophy and in normal men, Experientia 1979;35:844-845.
26. Horton R, Hsieh P, Barbcria J, Pages L, Cosgrove M: Altered blood androgens in elderly mer, with prostate hyperplasia, J Clin Endocrinol Metab 1975;41:793-796.
27. Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K, Yamanaka H, Honma S: Endocrine environment of benign prostatic hyperplasia: Prostate size and volume are correlated with serum estrogen concentration, Scand J Urol Nephrol 1995;29:65-68.
28. Skoldefors H, Blomstedt B, Carlstrom K: Serum hormone levels in benign prostatic hyperplasia, Scand J Urol Nephrol 1978; 12:111-114.
29. Geller J: Benign prostatic hyperplasia: Pathogenesis and medical therapy, J Am Geriatr Soc 1991:39:1208-1216.
30. Schweikert HU, Tunn UW, Habenicht UF, Arnold J, Senge T, Schulze H, Schroder FH, Blom JH, Ennemoser O, Horniger W, et al: Effects of estrogen deprivation of human benign prostatic hyperplasia, J Steroid Biochem Mol Biol 1993;44:573-576.
31. Isaace JT, Coffey DS: Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia, Endocrinology 1981;108:445-453.
32. Drafta D, Proca E, Zamfir V, Schindler AE, Ncacsu E, Stroe E: Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate, J Steroid Biochcm 1982;17:689-693.
33. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age, J Urol 1984;132:474-479.
34. Heaton KW: Diet and diverticulosis - New leads, Gut 1985;28:541-543.
35. Geller J: Basis for hormonal management of advanced prostate cancer, Cancer 1993.71: 1039-1045.